Literature DB >> 3093537

Asymptomatic carriage of Clostridium difficile in patients with cystic fibrosis.

S L Peach, S P Borriello, H Gaya, F E Barclay, A R Welch.   

Abstract

Faecal samples from 37 patients with cystic fibrosis and 40 control patients at the Brompton Hospital and the London Chest Hospital were examined for the presence of Clostridium difficile. The organism was isolated from 2 (17%) of control patients who were receiving antibiotics and from one (3.6%) of control patients who had no antimicrobial treatment. Thirty two per cent of the patients with cystic fibrosis excreted C difficile, though none of them had diarrhoea. Two of the three isolates from control patients and nine of the 12 isolates from patients with cystic fibrosis produced toxin B (cytotoxin) in vitro. Toxin B was present in the stools of one of the control patients and three of the patients with cystic fibrosis; toxin A (enterotoxin) was not detected in the faeces of the patients with cystic fibrosis. Two cytotoxigenic strains of C difficile isolated from patients with cystic fibrosis were examined in hamsters; both were virulent, and the animals died.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3093537      PMCID: PMC500203          DOI: 10.1136/jcp.39.9.1013

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  11 in total

1.  Growth of Clostridium difficile and production of toxins A and B in complex and defined media.

Authors:  S C Haslam; J M Ketley; T J Mitchell; J Stephen; D W Burdon; D C Candy
Journal:  J Med Microbiol       Date:  1986-06       Impact factor: 2.472

2.  Epidemiology of experimental enterocecitis due to Clostridium difficile.

Authors:  H E Larson; A B Price; S P Borriello
Journal:  J Infect Dis       Date:  1980-09       Impact factor: 5.226

3.  Protection of hamsters against Clostridium difficile ileocaecitis by prior colonisation with non-pathogenic strains.

Authors:  S P Borriello; F E Barclay
Journal:  J Med Microbiol       Date:  1985-06       Impact factor: 2.472

4.  Epidemiology of Clostridium difficile in infants.

Authors:  H E Larson; F E Barclay; P Honour; I D Hill
Journal:  J Infect Dis       Date:  1982-12       Impact factor: 5.226

5.  Selective and differential medium for isolation of Clostridium difficile.

Authors:  W L George; V L Sutter; D Citron; S M Finegold
Journal:  J Clin Microbiol       Date:  1979-02       Impact factor: 5.948

6.  Clostridium difficile in patients with cystic fibrosis.

Authors:  C J Welkon; S S Long; C M Thompson; P H Gilligan
Journal:  Am J Dis Child       Date:  1985-08

7.  Investigation of tissue organelles by a combination of analytical subcellular fractionation and enzymic microanalysis: a new approach to pathology.

Authors:  T J Peters
Journal:  J Clin Pathol       Date:  1981-01       Impact factor: 3.411

8.  Pseudomembranous colitis: Presence of clostridial toxin.

Authors:  H E Larson; A B Price
Journal:  Lancet       Date:  1977 Dec 24-31       Impact factor: 79.321

9.  An in-vitro model of colonisation resistance to Clostridium difficile infection.

Authors:  S P Borriello; F E Barclay
Journal:  J Med Microbiol       Date:  1986-06       Impact factor: 2.472

10.  Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations.

Authors:  R Viscidi; S Willey; J G Bartlett
Journal:  Gastroenterology       Date:  1981-07       Impact factor: 22.682

View more
  22 in total

1.  Clostridium difficile colitis in children with cystic fibrosis.

Authors:  Sunny Zaheed Hussain; Cathy Chu; David P Greenberg; David Orenstein; Seema Khan
Journal:  Dig Dis Sci       Date:  2004-01       Impact factor: 3.199

2.  Binary toxin and its clinical importance in Clostridium difficile infection, Belgium.

Authors:  T Pilate; J Verhaegen; M Van Ranst; V Saegeman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-07-08       Impact factor: 3.267

3.  Profiling Humoral Immune Responses to Clostridium difficile-Specific Antigens by Protein Microarray Analysis.

Authors:  Ola H Negm; Mohamed R Hamed; Elizabeth M Dilnot; Clifford C Shone; Izabela Marszalowska; Mark Lynch; Christine E Loscher; Laura J Edwards; Patrick J Tighe; Mark H Wilcox; Tanya M Monaghan
Journal:  Clin Vaccine Immunol       Date:  2015-07-15

4.  Pseudomembranous colitis in four patients with cystic fibrosis following lung transplantation.

Authors:  B Yates; D M Murphy; A J Fisher; F K Gould; J L Lordan; J H Dark; P A Corris
Journal:  BMJ Case Rep       Date:  2009-05-08

5.  Analysis of latex agglutination test for Clostridium difficile toxin A (D-1) and differentiation between C difficile toxins A and B and latex reactive protein.

Authors:  S P Borriello; F E Barclay; P J Reed; A R Welch; J D Brown; D W Burdon
Journal:  J Clin Pathol       Date:  1987-05       Impact factor: 3.411

6.  A new role for heat shock factor 27 in the pathophysiology of Clostridium difficile toxin B.

Authors:  Murali K Yanda; William B Guggino; Liudmila Cebotaru
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-11-11       Impact factor: 4.052

Review 7.  Clostridium difficile: its disease and toxins.

Authors:  D M Lyerly; H C Krivan; T D Wilkins
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

8.  Comparison of four commercially available rapid enzyme immunoassays with cytotoxin assay for detection of Clostridium difficile toxin(s) from stool specimens.

Authors:  C S Merz; C Kramer; M Forman; L Gluck; K Mills; K Senft; I Steiman; N Wallace; P Charache
Journal:  J Clin Microbiol       Date:  1994-05       Impact factor: 5.948

9.  Comparison of media for screening of diarrheic stools for the recovery of Clostridium difficile.

Authors:  P C Iwen; S J Booth; G L Woods
Journal:  J Clin Microbiol       Date:  1989-09       Impact factor: 5.948

10.  Survey of incidence of Clostridium difficile infection in Canadian hospitals and diagnostic approaches.

Authors:  M J Alfa; T Du; G Beda
Journal:  J Clin Microbiol       Date:  1998-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.